Trial Profile

DALVANCE utilisation registry investigating value and efficacy: outcomes report on real world use

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalbavancin (Primary)
Indications Bacterial endocarditis; Bacterial infections; Gram-positive infections; Skin infections
Focus Therapeutic Use

Most Recent Events

25 Oct 2020 Results presented at the IDWeek 2020
27 May 2019 New trial record
16 Apr 2019 Interim results (n=500) assessing real-world use of dalbavancin in ABSSSI and non-ABSSSI adults presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com